Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd Clarifies on news item
With reference to news appeared in www.business-standard.com dated December 03, 2017 quoting "Green panel nod to Jubilant Life's Rs 250-cr pesticide project in Gujarat", Jubilant Life Sciences Ltd has submitted to BSE a copy of Clarification is enclosed. Jubilant Life Sciences up 5% on talk of green panel for pesticide project
The stock of an integrated global pharmaceutical and life sciences company has rallied 14% in past three trading sessions. Clarification sought from Jubilant Life Sciences Ltd
The Exchange has sought clarification from Jubilant Life Sciences Ltd on December 04, 2017 with reference to news appeared in www.business-standard.com dated December 03, 2017 quoting "Green panel nod to Jubilant Life's Rs 250-cr pesticide project in Gujarat". The reply is awaited. Updates
Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that Drug Discovery and Development Solutions Limited, Singapore ('DDDSL'), a wholly-owned subsidiary company, has entered into Stock Purchase Agreement for acquiring entire Equity Share capital of Jubilant Discovery Services Inc., USA ('JDSI') on November 21, 2017, subject to applicable laws.... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd Jubilant Life's net profit drops by 12.6% to Rs. 125 cr in Q2
Jubilant Life Sciences, a Rs. 5,750 crore plus pharma major, has reported lower consolidated net profit of Rs. 125 crore during the second quarter ended September 2017 as compared to Rs. 144 crore in the similar quarter Updates
In continuation of our letter dated October 28, 2017, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended September 30, 2017 published on October 29, 2017 in Financial Express (English) and HINDUSTAN (Hindi).